Cargando…

Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy

Peripartum cardiomyopathy (PPCM) is a life-threatening heart disease developing towards the end of pregnancy or in the months following delivery in previously healthy women in terms of cardiac disease. Enhanced oxidative stress and the subsequent cleavage of the nursing hormone Prolactin into an ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Haghikia, A., Podewski, E., Libhaber, E., Labidi, S., Fischer, D., Roentgen, P., Tsikas, D., Jordan, J., Lichtinghagen, R., von Kaisenberg, C. S., Struman, I., Bovy, N., Sliwa, K., Bauersachs, J., Hilfiker-Kleiner, Denise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709080/
https://www.ncbi.nlm.nih.gov/pubmed/23812247
http://dx.doi.org/10.1007/s00395-013-0366-9
_version_ 1782276701528522752
author Haghikia, A.
Podewski, E.
Libhaber, E.
Labidi, S.
Fischer, D.
Roentgen, P.
Tsikas, D.
Jordan, J.
Lichtinghagen, R.
von Kaisenberg, C. S.
Struman, I.
Bovy, N.
Sliwa, K.
Bauersachs, J.
Hilfiker-Kleiner, Denise
author_facet Haghikia, A.
Podewski, E.
Libhaber, E.
Labidi, S.
Fischer, D.
Roentgen, P.
Tsikas, D.
Jordan, J.
Lichtinghagen, R.
von Kaisenberg, C. S.
Struman, I.
Bovy, N.
Sliwa, K.
Bauersachs, J.
Hilfiker-Kleiner, Denise
author_sort Haghikia, A.
collection PubMed
description Peripartum cardiomyopathy (PPCM) is a life-threatening heart disease developing towards the end of pregnancy or in the months following delivery in previously healthy women in terms of cardiac disease. Enhanced oxidative stress and the subsequent cleavage of the nursing hormone Prolactin into an anti-angiogenic 16 kDa subfragment emerged as a potential causal factor of the disease. We established a prospective registry with confirmed PPCM present in 115 patients (mean baseline left ventricular ejection fraction, LVEF: 27 ± 9 %). Follow-up data (6 ± 3 months) showed LVEF improvement in 85 % and full recovery in 47 % while 15 % failed to recover with death in 2 % of patients. A positive family history of cardiomyopathy was present in 16.5 %. Pregnancy-associated hypertension was associated with a better outcome while a baseline LVEF ≤ 25 % was associated with a worse outcome. A high recovery rate (96 %) was observed in patients obtaining combination therapy with beta-blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor-blockers (ARBs) and bromocriptine. Increased serum levels of Cathepsin D, the enzyme that generates 16 kDa Prolactin, miR-146a, a direct target of 16 kDa Prolactin, N-terminal-pro-brain-natriuretic peptide (NT-proBNP) and asymmetric dimethylarginine (ADMA) emerged as biomarkers for PPCM. In conclusion, low baseline LVEF is a predictor for poor outcome while pregnancy-induced hypertensive disorders are associated with a better outcome in this European PPCM cohort. The high recovery rate in this collective is associated with a treatment concept using beta-blockers, ACE inhibitors/ARBs and bromocriptine. Increased levels of Cathepsin D activity, miR-146a and ADMA in serum of PPCM patients support the pathophysiological role of 16 kDa Prolactin for PPCM and may be used as a specific diagnostic marker profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-013-0366-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3709080
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-37090802013-07-15 Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy Haghikia, A. Podewski, E. Libhaber, E. Labidi, S. Fischer, D. Roentgen, P. Tsikas, D. Jordan, J. Lichtinghagen, R. von Kaisenberg, C. S. Struman, I. Bovy, N. Sliwa, K. Bauersachs, J. Hilfiker-Kleiner, Denise Basic Res Cardiol Original Contribution Peripartum cardiomyopathy (PPCM) is a life-threatening heart disease developing towards the end of pregnancy or in the months following delivery in previously healthy women in terms of cardiac disease. Enhanced oxidative stress and the subsequent cleavage of the nursing hormone Prolactin into an anti-angiogenic 16 kDa subfragment emerged as a potential causal factor of the disease. We established a prospective registry with confirmed PPCM present in 115 patients (mean baseline left ventricular ejection fraction, LVEF: 27 ± 9 %). Follow-up data (6 ± 3 months) showed LVEF improvement in 85 % and full recovery in 47 % while 15 % failed to recover with death in 2 % of patients. A positive family history of cardiomyopathy was present in 16.5 %. Pregnancy-associated hypertension was associated with a better outcome while a baseline LVEF ≤ 25 % was associated with a worse outcome. A high recovery rate (96 %) was observed in patients obtaining combination therapy with beta-blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor-blockers (ARBs) and bromocriptine. Increased serum levels of Cathepsin D, the enzyme that generates 16 kDa Prolactin, miR-146a, a direct target of 16 kDa Prolactin, N-terminal-pro-brain-natriuretic peptide (NT-proBNP) and asymmetric dimethylarginine (ADMA) emerged as biomarkers for PPCM. In conclusion, low baseline LVEF is a predictor for poor outcome while pregnancy-induced hypertensive disorders are associated with a better outcome in this European PPCM cohort. The high recovery rate in this collective is associated with a treatment concept using beta-blockers, ACE inhibitors/ARBs and bromocriptine. Increased levels of Cathepsin D activity, miR-146a and ADMA in serum of PPCM patients support the pathophysiological role of 16 kDa Prolactin for PPCM and may be used as a specific diagnostic marker profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-013-0366-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2013-06-28 2013 /pmc/articles/PMC3709080/ /pubmed/23812247 http://dx.doi.org/10.1007/s00395-013-0366-9 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Contribution
Haghikia, A.
Podewski, E.
Libhaber, E.
Labidi, S.
Fischer, D.
Roentgen, P.
Tsikas, D.
Jordan, J.
Lichtinghagen, R.
von Kaisenberg, C. S.
Struman, I.
Bovy, N.
Sliwa, K.
Bauersachs, J.
Hilfiker-Kleiner, Denise
Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy
title Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy
title_full Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy
title_fullStr Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy
title_full_unstemmed Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy
title_short Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy
title_sort phenotyping and outcome on contemporary management in a german cohort of patients with peripartum cardiomyopathy
topic Original Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709080/
https://www.ncbi.nlm.nih.gov/pubmed/23812247
http://dx.doi.org/10.1007/s00395-013-0366-9
work_keys_str_mv AT haghikiaa phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT podewskie phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT libhabere phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT labidis phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT fischerd phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT roentgenp phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT tsikasd phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT jordanj phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT lichtinghagenr phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT vonkaisenbergcs phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT strumani phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT bovyn phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT sliwak phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT bauersachsj phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy
AT hilfikerkleinerdenise phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy